Skip to main content
. 2022 Apr 5;86(3):1399–1413. doi: 10.3233/JAD-215511

Fig. 7.

Fig. 7

Effect of fosgonimeton on ERP P300 latency in AD subjects. ERP P300 analysis of AD subjects demonstrates a significant reduction in ERP P300 latency following fosgonimeton (40 mg, OD, SC) administration. ERP (auditory oddball paradigm) was assessed at predose, and 1 hour and 3 hours postdose on treatment day 1, 4, and 8. A) Heat maps of the group average ERP P300 latency data expressed in milliseconds (ms) for the AD subjects received fosgonimeton active treatment (n = 7). B) All subjects receiving fosgonimeton (n = 7) demonstrated reduced ERP P300 latency from baseline to end of study for ERP on day 8, while subjects receiving placebo demonstrated no consistent change from baseline. C) ERP P300 latency changes from baseline over the 8-day treatment for fosgonimeton (n = 7) compared to placebo (n = 4). Data shown are mean ERP P300 values from Fz, Cz, Pz electrodes±SEM. *p = 0.027 with MMRM analysis. AD, Alzheimer’s disease; ERP, event-related potential; MMRM, mixed effect model repeat measurement; OD, once daily; SC, subcutaneous; SEM, standard error of the mean.